Logo image of CODX

CO-DIAGNOSTICS INC (CODX) Stock Fundamental Analysis

USA - NASDAQ:CODX - US1897631057 - Common Stock

0.3242 USD
-0.03 (-7.4%)
Last: 10/17/2025, 8:03:54 PM
0.3243 USD
+0 (+0.03%)
After Hours: 10/17/2025, 8:03:54 PM
Fundamental Rating

3

CODX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. CODX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CODX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CODX has reported negative net income.
CODX had a negative operating cash flow in the past year.
In multiple years CODX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CODX reported negative operating cash flow in multiple years.
CODX Yearly Net Income VS EBIT VS OCF VS FCFCODX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

CODX's Return On Assets of -77.46% is on the low side compared to the rest of the industry. CODX is outperformed by 72.77% of its industry peers.
With a Return On Equity value of -87.49%, CODX is not doing good in the industry: 60.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -77.46%
ROE -87.49%
ROIC N/A
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
CODX Yearly ROA, ROE, ROICCODX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

CODX's Gross Margin of 39.61% is on the low side compared to the rest of the industry. CODX is outperformed by 66.49% of its industry peers.
CODX's Gross Margin has improved in the last couple of years.
CODX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
CODX Yearly Profit, Operating, Gross MarginsCODX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

CODX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CODX has more shares outstanding than it did 1 year ago.
CODX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CODX Yearly Shares OutstandingCODX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CODX Yearly Total Debt VS Total AssetsCODX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.13, we must say that CODX is in the distress zone and has some risk of bankruptcy.
CODX has a Altman-Z score of -2.13. This is in the lower half of the industry: CODX underperforms 63.35% of its industry peers.
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.13
ROIC/WACCN/A
WACC8.66%
CODX Yearly LT Debt VS Equity VS FCFCODX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CODX has a Current Ratio of 4.12. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CODX (4.12) is better than 71.20% of its industry peers.
CODX has a Quick Ratio of 3.83. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
CODX has a Quick ratio of 3.83. This is in the better half of the industry: CODX outperforms 73.30% of its industry peers.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.83
CODX Yearly Current Assets VS Current LiabilitesCODX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

CODX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Looking at the last year, CODX shows a very negative growth in Revenue. The Revenue has decreased by -89.02% in the last year.
CODX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.52% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.29%
Revenue 1Y (TTM)-89.02%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-93.87%

3.2 Future

CODX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.59% yearly.
CODX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 171.12% yearly.
EPS Next Y31.85%
EPS Next 2Y32.18%
EPS Next 3Y24.07%
EPS Next 5Y28.59%
Revenue Next Year-87.61%
Revenue Next 2Y-59.63%
Revenue Next 3Y111.18%
Revenue Next 5Y171.12%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CODX Yearly Revenue VS EstimatesCODX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CODX Yearly EPS VS EstimatesCODX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CODX. In the last year negative earnings were reported.
Also next year CODX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CODX Price Earnings VS Forward Price EarningsCODX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CODX Per share dataCODX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CODX's earnings are expected to grow with 24.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.18%
EPS Next 3Y24.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CODX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CO-DIAGNOSTICS INC

NASDAQ:CODX (10/17/2025, 8:03:54 PM)

After market: 0.3243 +0 (+0.03%)

0.3242

-0.03 (-7.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-06 2025-11-06
Inst Owners25.94%
Inst Owner Change0%
Ins Owners7.88%
Ins Owner Change5.49%
Market Cap15.61M
Analysts80
Price Target2.04 (529.24%)
Short Float %2.24%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.16%
Min EPS beat(2)28.7%
Max EPS beat(2)63.63%
EPS beat(4)3
Avg EPS beat(4)23.36%
Min EPS beat(4)-3.81%
Max EPS beat(4)63.63%
EPS beat(8)5
Avg EPS beat(8)-0.54%
EPS beat(12)7
Avg EPS beat(12)-29.57%
EPS beat(16)10
Avg EPS beat(16)-16.2%
Revenue beat(2)1
Avg Revenue beat(2)-40.16%
Min Revenue beat(2)-86.85%
Max Revenue beat(2)6.54%
Revenue beat(4)2
Avg Revenue beat(4)-18.44%
Min Revenue beat(4)-86.85%
Max Revenue beat(4)67.62%
Revenue beat(8)4
Avg Revenue beat(8)192.06%
Revenue beat(12)4
Avg Revenue beat(12)109.7%
Revenue beat(16)6
Avg Revenue beat(16)78.9%
PT rev (1m)-63.64%
PT rev (3m)-63.64%
EPS NQ rev (1m)-12.9%
EPS NQ rev (3m)-25%
EPS NY rev (1m)-3.42%
EPS NY rev (3m)29.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.55
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.02
BVpS0.85
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.46%
ROE -87.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.61%
FCFM N/A
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.84%
Cap/Sales 73.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 3.83
Altman-Z -2.13
F-Score2
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)92.34%
Cap/Depr(5y)204.81%
Cap/Sales(3y)14.45%
Cap/Sales(5y)9.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.29%
EPS Next Y31.85%
EPS Next 2Y32.18%
EPS Next 3Y24.07%
EPS Next 5Y28.59%
Revenue 1Y (TTM)-89.02%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-93.87%
Revenue Next Year-87.61%
Revenue Next 2Y-59.63%
Revenue Next 3Y111.18%
Revenue Next 5Y171.12%
EBIT growth 1Y-0.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-124.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.92%
OCF growth 3YN/A
OCF growth 5YN/A